Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s4, 2021. DOI: 10.25251/skin.5.supp.4. Disponível em: https://skin.dermsquared.com/skin/article/view/1156. Acesso em: 19 apr. 2025.